Danaher's $20B Masimo Deal Reshapes Medical Tech Landscape by 2026

Danaher has agreed to acquire Masimo in one of the largest medical technology deals in recent years. The all-cash transaction will combine Masimo's real-time patient monitoring with Danaher's diagnostics expertise. Both companies' boards have approved the move, pending shareholder and regulatory approvals.

The deal is set to close in the second half of 2026. Funding will come from Danaher's existing cash reserves and new debt. Once completed, it will merge Masimo's Signal Extraction Technology (SET) with Danaher's diagnostics brands, including Cepheid and Radiometer.

Masimo will remain a standalone company under Danaher's umbrella. This structure aims to retain its brand while tapping into Danaher's global reach and operational systems. The acquisition is projected to add $0.15 to $0.20 to Danaher's adjusted earnings per share in the first full year, rising to around $0.70 by the fifth year.

Danaher expects annual cost savings of over $125 million and revenue synergies exceeding $50 million within five years. The move follows a pattern of growth: since acquiring Abcam in September 2023, Danaher's market capitalisation has climbed by roughly 45% to $195 billion as of February 2026. This outpaces gains from earlier deals like Cytiva (30%) and Aldevron (25%), though it falls short of the 55% surge after the IDT acquisition in 2022.

Meanwhile, Danaher's stock currently trades at €177.50, about 1.75% below its 200-day moving average. The share price has dropped nearly 10% since the start of the year.

The acquisition will link laboratory diagnostics with real-time bedside monitoring. Regulatory and shareholder approvals remain the final hurdles before completion. If successful, the deal will reshape Danaher's position in the medical technology sector.